Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

NCT ID: NCT03552068

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-15
• Study Completion Date: 2021-12-03

Brief Summary

Noradrenergic system is involved in impulsivity in the general population and is altered in Parkinson's disease (PD) in the early stages of the disease. Thus, targeting this system could be of interest in impulse control disorder (ICD). Acting on the noradrenergic system is possible using clonidine, an α2 adrenergic agonist largely used in hypertension treatment and that induces a decrease of NADR release. Thus, our aim is to conduct a proof of concept study evaluating the efficacy and safety of clonidine on ICD in PD. This study is a multicenter, randomized, double-blind, placebo-controlled in parallel group clinical trial.

Conditions

Parkinson's Disease; Mpulse Control Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Patients under placebo

Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.

Medication: placebo twice a day (in the morning and evening).

Patient under clonidine

Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.

Group Type: ACTIVE_COMPARATOR

Clonidine

Intervention Type: DRUG

Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).

Interventions

placebo

Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.

Medication: placebo twice a day (in the morning and evening).

Intervention Type: DRUG

Clonidine

Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with PD according to MDS (movement disorders society) criteria for at least one year
• Patients with ICD with a QUIP-RS score ≥10 and/or at least one of the sub-scores in the following range: Pathological gambling between >6 and 12; Pathological gambling between >8 and 12; Hypersexuality between > 8 and 12; Eating between > 7 and 12. The use of "lower" margins will guarantee that patients will present behavioral disturbances severe enough to justify clonidine treatment. On the other hand, the use of "upper" margins will guarantee that the patients included in the trial will not suffer from ICD too severe to ethically participate to a placebo controlled study.
• Weight between 40 and 95kg
• Stable antiparkinsonian medication since at least 2 months before randomization and medication supposed to remain stable during the study
• ICD onset after Parkinson's disease onset and after initiation of dopaminergic drugs
• No signs of dementia (Montreal Cognitive Assessment, MOCA >20);
• No lactose intolerance which may compromise the tolerance of the placebo;
• Patients with health insurance
• Patients without judicial protection measure except directly linked to ICD
• For women of childbearing potential, an effective contraception method for at least 2 months before randomization (as implants or oral oestro-progestative contraceptives), condom use for men during the study. βHCG dosage in urine should be negative at randomization for women.

Exclusion Criteria

Patients with major depression (BDI >19);

• Patients with another parkinsonian syndrome (Parkinson "plus" or vascular Parkinsonism)
• Orthostatic hypotension
• Patients with swallowing disorders that may prevent oral medication,
• Contraindication to clonidine: Hypersensibility; Severe bradyarythmia due to a cardiac disease
• Patients receiving a treatment potentially interacting with clonidine
• Patients with Raynaud's disease or obliterating thromboangiitis
• Patients With Heart failure or severe coronary artery disease
• Patients with a drug treatment having a potential interaction with clonidine (see list, appendix 2);
• Presence of renal failure (Cockcroft-Gault at inclusion visit<30 ml/min/1,73m2);
• Patients with a present or past history of addiction (apart ICD) or with a substance abuse (except Tabaco)
• Pregnant or lactating women
• Already participating in another biomedical research project

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

LAURENCIN Chloé, Dr

Role: STUDY_DIRECTOR

Hospices Civils de Lyon

Locations

Hospices Civils de Lyon

Bron, , France

Countries

France

References

Laurencin C, Timestit N, Marques A, Duchez DD, Giordana C, Meoni S, Huddlestone M, Danaila T, Anheim M, Klinger H, Vidal T, Fatisson M, Caire C, Nourredine M, Boulinguez P, Dhelens C, Ballanger B, Prange S, Bin S, Thobois S. Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial. J Neurol. 2023 Oct;270(10):4851-4859. doi: 10.1007/s00415-023-11814-y. Epub 2023 Jun 20.

Reference Type: BACKGROUND

PMID: 37338615 (View on PubMed)

Other Identifiers

2019-000165-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

69HCL18_0135

Identifier Type: -

Identifier Source: org_study_id